La prochaine rencontre, qui aura lieu le 10 novembre à Mila, permettra d'explorer comment pouvons-nous collectivement développer, encadrer et déployer des systèmes agentiques performants, fiables et sécuritaires en connectant chercheur·euse·s académiques, expert·e·s industriel·le·s et praticien·ne·s.
Les inscriptions sont ouvertes pour notre programme de 4 mois à temps plein, à Mila, conçu spécifiquement pour les fondateurs et fondatrices de la deep tech issus de parcours d'élite en STIM. Vous avez jusqu'au 21 novembre 2026 pour appliquer!
Le processus de demandes de supervision à Mila est maintenant ouvert! Vous pouvez appliquer dès maintenant à la maitrise de recherche ou Doctorat et joindre notre grande communauté de chercheur·euse·s à Mila pour l’automne 2027. Date limite : 1er décembre 2026
Nous utilisons des témoins pour analyser le trafic et l’utilisation de notre site web, afin de personnaliser votre expérience. Vous pouvez désactiver ces technologies à tout moment, mais cela peut restreindre certaines fonctionnalités du site. Consultez notre Politique de protection de la vie privée pour en savoir plus.
Paramètre des cookies
Vous pouvez activer et désactiver les types de cookies que vous souhaitez accepter. Cependant certains choix que vous ferez pourraient affecter les services proposés sur nos sites (ex : suggestions, annonces personnalisées, etc.).
Cookies essentiels
Ces cookies sont nécessaires au fonctionnement du site et ne peuvent être désactivés. (Toujours actif)
Cookies analyse
Acceptez-vous l'utilisation de cookies pour mesurer l'audience de nos sites ?
Lecteur Multimédia
Acceptez-vous l'utilisation de cookies pour afficher et vous permettre de regarder les contenus vidéo hébergés par nos partenaires (YouTube, etc.) ?
Background and purpose: Although radiotherapy response involves biological processes shared across cancers, most biomarker studies rely on s… (voir plus)mall, disease-specific sample sizes that limit the reliability of prognostic models. This study evaluated whether pan-cancer data can increase the information available for estimating genomic associations with progression after radiotherapy, based on Molecular Signatures Database hallmark gene sets applied to The Cancer Genome Atlas patients. Methods and materials: Cross-cancer predictive potential was evaluated in cancer types with at least 100 patients who received radiotherapy and had information on gene expression, progression, age, stage, and gender: breast invasive carcinoma (BRCA, n=553), cervical squamous cell carcinoma (CESC, n=183), head-neck squamous cell carcinoma (HNSC, n=320), low-grade glioma (LGG, n=316), lung adenocarcinoma (LUAD, n=104), skin cutaneous melanoma (SKCM, n=125), thyroid cancer (THCA, n=326), and uterine corpus endometrial carcinoma (UCEC, n=257). Gene set expression scores were calculated at the single-sample level. For each evaluation cancer type, scores from all other types were used to fit pan-cancer Cox proportional hazards models. Linear predictions from these models were evaluated in per-cancer prognostication via Kaplan Meier curves, Cox proportional hazards (CoxPH) estimates, including adjustment for age, stage, and gender, and optimism-corrected C-statistic and Nagelkerke pseudo-R 2 . Results: In Kaplan Meier analysis, pan-cancer scores predicted progression in all cancer types, with varying statistical significance. Univariable CoxPH models also demonstrated consistent association with progression, again with varying significance. Associations persisted when adjusted for clinical variables, and model performance metrics indicated the potential to improve per-cancer prognostication. Associations were particularly strong for BRCA, CESC, HNSC, LGG, and LUAD, with statistically insignificant results for SKCM, THCA, and UCEC. Conclusion: Pan-cancer gene expression data can predict per-cancer progression after radiotherapy, with variable strength across cancer types. These findings support the use of cross-cancer genomic information to address sample size limitations that affect radiotherapy biomarker development.
Background and Purpose: Radiotherapy targets DNA in cancer cell nuclei. Radiation dose, however, is prescribed to a macroscopic target volum… (voir plus)e assuming uniform distribution, failing to consider microscopic variations in dose absorbed by individual nuclei. This study investigated a potential link between pre-treatment tumour nuclear size distributions and post-radiotherapy outcomes in gynecological squamous cell carcinoma (SCC). Materials and Methods: Our multi-institutional cohort consisted of 191 non-metastatic gynecological SCC patients who had received radiotherapy with diagnostic whole slide images (WSIs) available. Tumour nuclear size distribution mean and standard deviation were extracted from WSIs using deep learning, and used to predict progression-free interval (PFI) and overall survival (OS) in multivariate Cox proportional hazards (CoxPH) analysis adjusted for age and clinical stage. Results: Multivariate CoxPH analysis revealed that a larger nuclear size distribution mean results in more favorable outcomes for PFI (HR = 0.45, 95% CI: 0.19 - 1.09, p = 0.084) and OS (HR = 0.55, 95% CI: 0.24 - 1.25, p = 0.16), and that a larger nuclear size standard deviation results in less favorable outcomes for PFI (HR = 7.52, 95% CI: 1.43 - 39.52, p = 0.023) and OS (HR = 4.67, 95% CI: 0.96 - 22.57, p = 0.063). The bootstrap-validated C-statistic was 0.56 for PFI and 0.57 for OS. Conclusion: Despite low accuracy, tumour nuclear size heterogeneity aided prognostication over standard clinical variables and was associated with outcomes following radiotherapy in gynecological SCC. This highlights the potential importance of personalized multiscale dosimetry and warrants further large-scale pan-cancer studies.
2025-06-18
Physics and Imaging in Radiation Oncology (publié)